From the Journals

Engineering CAR T Cells to Resist Tumor Immune Suppression

CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models

  • By

  • March 9, 2026

  • 2 min

Share

A study from Ludwig-Maximilians-Universität München reveals that genetically modified CAR T cells, engineered to bypass a major immunosuppressive mechanism in tumors, can enhance treatment efficacy for solid cancers. By using CRISPR–Cas9 to disable EP2 and EP4 receptors associated with prostaglandin E2 (PGE2), these modified CAR T cells showed improved persistence and activity in tumor environments, leading to better control of pancreatic cancer, melanoma, and other tumor types in preclinical models. Ongoing research aims to bring these findings into clinical applications.

Original Source(s)

Engineering CAR T Cells to Resist Tumor Immune Suppression

CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models

  • March 9, 2026

  • 2 min

Related Content

Accelerating Structure-based Drug Design for Complex Membrane Proteins

Nuclera and leadXpro partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets

  • March 9, 2026

  • 3 min
Are AI Models Cheating in Biomarker Predictions?

Study finds image-based predictions often reflect confounding factors rather than true molecular signals

  • March 6, 2026

  • 3 min
The Strategic Role of CRA AI Agents in Clinical Research

Using agentic AI to reduce clinical trial inefficiency